PSMA-Targeting Imprinted Nanogels for Prostate Tumor Localization and Imaging

Area of Science:

• Biomaterials Science
• Nanotechnology
• Oncology

Background:

• Prostate-specific membrane antigen (PSMA) is a key biomarker overexpressed in prostate cancer.
• Existing PSMA-targeting agents like antibodies and small molecules have limitations including instability, complex production, low specificity, and high toxicity.
• A novel synthetic antibody is needed to overcome these challenges for effective PSMA-directed cancer therapy.

Purpose of the Study:

• To develop and characterize a novel PSMA-targeting synthetic antibody, MIP-M, to address limitations of conventional agents.
• To evaluate the binding affinity, specificity, and targeting capability of MIP-M for PSMA.

Main Methods:

• Synthesis of fluorescently labeled, N-isopropylacrylamide-based epitope imprinted nanogels (MIP-M) using magnetic nanoparticles as templates and a linear PSMA epitope.
• Assessment of binding affinities to the epitope template and PSMA using established methods.
• Evaluation of specificity against reference peptides and human serum albumin.
• Flow cytometry and confocal laser scanning microscopy to compare MIP-M binding to prostate cancer cell lines (PC3 and LNCaP) with varying PSMA expression levels, alongside a PSMA antibody.

Main Results:

• MIP-M demonstrated high binding affinities for both the epitope template (K_D = 6 × 10^-10 M) and PSMA (K_D = 2.5 × 10^-9 M).
• MIP-M exhibited high specificity compared to reference peptides and human serum albumin.
• Flow cytometry and microscopy confirmed comparable binding preferences of MIP-M and a PSMA antibody for LNCaP cells (high PSMA expression).
• MIP-M showed selectivity for PSMA-positive prostate tumors over normal tissue, similar to the PSMA antibody.

Conclusions:

• The developed MIP-M synthetic antibody effectively targets PSMA with high affinity and specificity.
• MIP-M offers advantages over conventional agents by addressing limitations in stability, production, specificity, and toxicity.
• MIP-M represents a promising alternative for PSMA-directed prostate cancer diagnosis and treatment.